Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Letko Brosseau & Associates Inc.

Letko Brosseau & Associates Inc. increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 967,533 shares of the biopharmaceutical company's stock after purchasing an additional 17,075 shares during the quarter. Letko Brosseau & Associates Inc. owned 0.08% of Gilead Sciences worth $66,382,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Oxbow Advisors LLC acquired a new position in Gilead Sciences during the second quarter worth $4,909,000. Mosley Wealth Management lifted its stake in Gilead Sciences by 25.9% during the 2nd quarter. Mosley Wealth Management now owns 4,894 shares of the biopharmaceutical company's stock worth $336,000 after acquiring an additional 1,006 shares in the last quarter. Illinois Municipal Retirement Fund boosted its holdings in Gilead Sciences by 13.7% during the 2nd quarter. Illinois Municipal Retirement Fund now owns 272,384 shares of the biopharmaceutical company's stock valued at $18,688,000 after acquiring an additional 32,721 shares during the period. Seven Post Investment Office LP acquired a new position in Gilead Sciences in the 2nd quarter valued at about $804,000. Finally, Commonwealth Retirement Investments LLC purchased a new stake in Gilead Sciences during the second quarter worth about $1,556,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Cantor Fitzgerald reissued a "neutral" rating and issued a $70.00 price objective on shares of Gilead Sciences in a research note on Friday, August 9th. Robert W. Baird restated a "neutral" rating and issued a $80.00 price target on shares of Gilead Sciences in a research note on Thursday, June 20th. BMO Capital Markets upped their price objective on Gilead Sciences from $80.00 to $85.00 and gave the stock an "outperform" rating in a research report on Friday, August 9th. Truist Financial boosted their target price on Gilead Sciences from $82.00 to $83.00 and gave the stock a "hold" rating in a research note on Thursday, August 15th. Finally, Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Thursday, August 15th. Twelve equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $82.06.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares in the company, valued at $6,614,559.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Gilead Sciences news, insider Johanna Mercier sold 5,490 shares of the business's stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total value of $406,150.20. Following the transaction, the insider now directly owns 114,979 shares of the company's stock, valued at approximately $8,506,146.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now owns 96,380 shares of the company's stock, valued at approximately $6,614,559.40. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Gilead Sciences Stock Down 0.1 %

NASDAQ:GILD traded down $0.05 during midday trading on Friday, hitting $78.72. 9,220,980 shares of the company were exchanged, compared to its average volume of 7,163,236. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $87.86. The company has a market capitalization of $98.07 billion, a PE ratio of 218.67, a price-to-earnings-growth ratio of 2.74 and a beta of 0.18. The company has a fifty day simple moving average of $74.06 and a 200 day simple moving average of $70.57.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.61 by $0.40. The business had revenue of $6.95 billion for the quarter, compared to analysts' expectations of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be given a dividend of $0.77 per share. The ex-dividend date is Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.91%. Gilead Sciences's dividend payout ratio (DPR) is presently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.